Cereno Scientific

Cereno Scientific Extends Financial Runway by Extending Loan Maturity Date   On November 17, 2023, the Board of Directors of the Company decided to enter into a loan agreement of up to SEK 90 million issued by Formue Nord Fokus A/S, renamed to Fenja Capital II A/S (“Fenja Capital”), which matures for payment on May 14, 2025.   Cereno Scientific announces today, July 10, 2024, that the Board of Directors of the Company has decided to extend financial runway through loan maturity date extension, which will be achieved by entering into a new loan agreement with Fenja Capital replacing the current loan agreement, which means that the loan is extended until March 31, 2026.   Read the full press release: 

Cereno Scientific reports acquired warrants within the framework of the incentive program resolved at the Annual General Meeting   Members of the Company’s management who have acquired warrants of series 2024/2027:1 within the framework of the incentive program are: ·     Rahul Agrawal, CMO and Head of R&D: 2,000,000 warrants ·     Julia Fransson, Director of Business Development, 200,000 warrants ·     Tatiane Abreu Dall’Agnol, Medical Director, 200,000 warrants ·     Megha Ranjan, Project Director, 25,000 warrants   Read the full press release here:

New CEO Interview by BioStock! Cereno Scientific CEO Sten R. Sörensen comments on the latest progress with CS1 and CS014:

Cereno Scientific announces final milestone payment to Emeriti Bio for CS014   The CS014 program was acquired to complement Cereno’s cardiovascular portfolio and has since then been developed in a collaboration between Cereno Scientific, Emeriti Bio and University of Michigan. The agreement with Emeriti Bio signed in 2019 transferred all rights for CS014, and the related compound family, from Emeriti Bio to Cereno. This final milestone payment concludes all remuneration under the agreement.   Read the full press release here:

New article in Börs & Finans about Cereno Scientific breaking new ground within treatment of rare and common cardiovascular diseases   Sten R. Sörensen, CEO, Cereno Scientific, is featured in Börs & Finans, commenting on the Company’s pioneering drug development pipeline within epigenetic modulation through HDAC inhibition in rare and common cardiovascular diseases. Sörensen highlights Cereno’s accelerated growth phase with three innovative drug development projects, with the potential to have significant impact for patients in diseases with high unmet medical needs.   CS014 in development to prevent thrombosis entered clinical phase last week, after 5 years in development and CS1, the most advanced project, is targeted to deliver topline results from its phase II clinical trial in the rare disease Pulmonary Arterial Hypertension (PAH) in Q3 this year. Cereno on the go has just moved to new offices into the vibrant health care/biotech research community GoCo Health Innovation City in Gothenburg, Sweden.   Read the full article here (in Swedish):

First subject dosed in Cereno Scientific’s first-in-human Phase I trial of novel HDAC inhibitor CS014   The Phase I trial of CS014 will include around 48 subjects and results are expected in a year’s time.   Read the full press release here: https://lnkd.in/d7myQRYS

Cereno Scientific’s Phase II trial with CS1 in Pulmonary Arterial Hypertension is closing for recruitment and proceeding to topline   Based on a recommendation from the Study Clinical Steering Committee, Cereno Scientific has decided to close patient recruitment to study CS1-003 by July 1st, 2024. The Study Clinical Steering Committee concluded that there is sufficient data for evaluating the next steps in development. Topline results will be shared in Q3, 2024.   Read the full press release here: https://lnkd.in/d_Xhk4U7

New BioStock Interview with Cereno Scientific's CEO Sten R. Sörensen   BioStock has published an interview with Cereno Scientific's CEO Sten R. Sörensen, commenting on the approval by the EMA for a first-in-human Phase I trial of novel histone deacetylase inhibitor (HDACi) CS014, why this is such an important milestone for Cereno, and the potential of HDAC inhibition as a concept in cardiovascular disease.   See the interview here:

Cereno Scientific granted approval from EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014   The aim of the planned first-in-human Phase I trial is to evaluate the safety and tolerability of CS014 in healthy volunteers. The design is a single-ascending- and multiple-ascending-dose trial for 1 week. The title of the study is “A first-in-human, open-label trial to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of CS014 in healthy volunteers after single and multiple administration”. More information will be available on ClinicalTrials.gov shortly.   Read the full press release here:

Preclinical data for Cereno Scientific’s drug candidate CS585 showing high selectivity for the IP receptor presented at the EHA 2024 Hybrid Congress   The abstract titled “Superior Selectivity of CS585 to The Prostacyclin Receptor Translates to A New Viable Target for Prevention of Thrombosis”, was authored by L. Stanger, P Yalavarthi, A. Rickenberg, K. Goerger, D. Gilmore and M. Holinstat, at University of Michigan, Ann Arbor, USA; and B. Dahlöf, Cereno Scientific, Gothenburg, Sweden.   Read the full press release here: